News Merck gets stuck on Proxygen’s molecular glue degraders Proxygen has added another big pharma company to its list of partners, with Merck & Co the latest to be snared by its molecular glue degrader technology.
News Zymeworks cuts deal to buy Theravance for $929m in cash Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.